Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Sunday, May 31, 2015 2:26:44 PM
bullish
## source: finance.yahoo.com
Thu, 28 May 2015 15:30:00 GMT ~ Agenus to Present at the Jefferies 2015 Healthcare Conference
[Business Wire] - Agenus Inc. , an immunology company developing innovative treatments for cancers and other diseases, today announced that the Company will present at the Jefferies 2015 Healthcare Conference on Thursday, June 4th at 1:00 p.m.
read full: http://finance.yahoo.com/news/agenus-present-jefferies-2015-healthcare-153000024.html
*********************************************************
Wed, 27 May 2015 20:09:26 GMT ~ AGENUS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exh
read full: http://biz.yahoo.com/e/150527/agen8-k.html
*********************************************************
Wed, 27 May 2015 20:01:00 GMT ~ Agenus Announces Closing of Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock
[Business Wire] - Agenus Inc. , an immunology company developing innovative treatments for cancers and other diseases, today announced the closing of its public offering of 12,650,000 shares of common stock, offered at a price to the public of $6.30 per share, which includes the exercise in full by the underwriters of their option to purchase 1,650,000 additional shares of common stock.
read full: http://finance.yahoo.com/news/agenus-announces-closing-public-offering-200100037.html
*********************************************************
Wed, 27 May 2015 16:39:59 GMT ~ 4 stocks to watch
read full: http://www.marketwatch.com/News/Story/Story.aspx?guid=0CED20B1-F3CD-47BC-A94F-1F3B867043AB&siteid=yhoof2
*********************************************************
Thu, 21 May 2015 13:27:00 GMT ~ Agenus Announces Pricing of Its Public Offering of Common Stock
[Business Wire] - Agenus Inc. , an immunology company developing innovative treatments for cancers and other diseases, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $6.30 per share.
read full: http://finance.yahoo.com/news/agenus-announces-pricing-public-offering-132700743.html
*********************************************************
$AGEN charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$AGEN company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/AGEN/company-info
Ticker: $AGEN
OTC Market Place: Not Available
CIK code: 0001098972
Company name: Agenus Inc.
Incorporated In: DE, USA
Business Description:
$AGEN share structure
## source: otcmarkets.com
Market Value: $584,753,288 a/o May 29, 2015
Shares Outstanding: 71,485,732 a/o Apr 27, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$AGEN extra dd links
Company name: Agenus Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AGEN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AGEN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AGEN+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AGEN/news - http://finance.yahoo.com/q/h?s=AGEN+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AGEN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AGEN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AGEN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AGEN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Agenus+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Agenus+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Agenus+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AGEN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001098972&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AGEN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AGEN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AGEN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AGEN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AGEN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AGEN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AGEN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AGEN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AGEN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AGEN+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AGEN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AGEN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AGEN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AGEN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AGEN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AGEN/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AGEN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AGEN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AGEN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AGEN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AGEN
$AGEN DD Notes ~ http://www.ddnotesmaker.com/AGEN
Recent AGEN News
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) Shareholders • PR Newswire (US) • 09/16/2024 09:45:00 AM
- Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 • Business Wire • 09/13/2024 02:00:00 PM
- Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action • PR Newswire (US) • 09/11/2024 06:25:00 PM
- Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 • Business Wire • 09/09/2024 11:30:00 AM
- Agenus to Participate in September Investor Conferences • Business Wire • 09/03/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:49:59 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/08/2024 08:47:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:45:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:08:46 PM
- Agenus Reports Second Quarter 2024 Operational and Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Announces Appointment of Tom Harrison to Board of Directors • Business Wire • 08/08/2024 11:00:00 AM
- Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers • Business Wire • 08/07/2024 02:58:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:02:09 PM
- Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update • Business Wire • 07/26/2024 11:00:00 AM
- Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer • Business Wire • 07/18/2024 11:00:00 AM
- Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference • Business Wire • 06/28/2024 03:10:00 PM
- Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies • Business Wire • 06/27/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 08:05:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:05:01 PM
- Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors • Business Wire • 06/17/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:02:11 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM